Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea | Zendy

Jeongha Mok | Zendy; Hyungseok Kang | Zendy; Soo Hee Hwang | Zendy; Jin Su Park | Zendy; Bohyoung Kang | Zendy; Taehoon Lee | Zendy; WonJung Koh | Zendy; JaeJoon Yim | Zendy; Doosoo Jeon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea

Author(s) -

Jeongha Mok,

Hyungseok Kang,

Soo Hee Hwang,

Jin Su Park,

Bohyoung Kang,

Taehoon Lee,

WonJung Koh,

JaeJoon Yim,

Doosoo Jeon

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx373

Subject(s) - interim , medicine , extensively drug resistant tuberculosis , compassionate use , intensive care medicine , tuberculosis , mycobacterium tuberculosis , clinical trial , pathology , archaeology , history

Delamanid is a new anti-TB drug, but few data exist on its use outside clinical trials. The purpose of this study was to evaluate the efficacy as well as the safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of MDR- and XDR-TB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research